Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ALX ONCOLOGY HOLDINGS INC.

(ALXO)
  Report
Real-time Estimate Cboe BZX  -  02:36 2022-10-05 pm EDT
10.27 USD   -2.42%
08:02aALX Oncology Announces Trials in Progress Abstracts Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
GL
08:01aALX Oncology Announces Trials in Progress Abstracts Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
AQ
09/28Alx Oncology : Corporate Presentation
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ALX Oncology's Evorpacept Picked for New Treatment Arm in Breast Cancer Trial

08/16/2022 | 10:24am EDT


© MT Newswires 2022
All news about ALX ONCOLOGY HOLDINGS INC.
08:02aALX Oncology Announces Trials in Progress Abstracts Accepted for Poster Presentation at..
GL
08:01aALX Oncology Announces Trials in Progress Abstracts Accepted for Poster Presentation at..
AQ
09/28Alx Oncology : Corporate Presentation
PU
09/21ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
GL
09/21ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference
AQ
09/01ALX Oncology Announces Upcoming Investor Conference Participation
GL
08/26UBS Adjusts ALX Oncology Price Target to $31 From $37, Maintains Buy Rating
MT
08/16ALX Oncology's Evorpacept Picked for New Treatment Arm in Breast Cancer Trial
MT
08/16ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of..
PR
08/15Alx Oncology : Corporate Presentation
PU
More news
Analyst Recommendations on ALX ONCOLOGY HOLDINGS INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -126 M - -
Net cash 2022 247 M - -
P/E ratio 2022 -3,48x
Yield 2022 -
Capitalization 429 M 429 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 52
Free-Float 73,6%
Chart ALX ONCOLOGY HOLDINGS INC.
Duration : Period :
ALX Oncology Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALX ONCOLOGY HOLDINGS INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 10,52 $
Average target price 38,13 $
Spread / Average Target 262%
EPS Revisions
Managers and Directors
Jaume Pons President, Chief Executive Officer & Director
Peter S. García Chief Financial Officer
Corey S. Goodman Executive Chairman
Sophia Randolph Director & Chief Medical Officer
Michael Chang Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ALX ONCOLOGY HOLDINGS INC.-51.05%429
REGENERON PHARMACEUTICALS, INC.17.10%79 063
VERTEX PHARMACEUTICALS36.90%77 102
BIONTECH SE-46.64%33 432
WUXI APPTEC CO., LTD.-39.54%29 067
GENMAB A/S0.76%23 187